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Mechanisms of Artemisia scoparia’s Anti-Inflammatory 
Activity in Cultured Adipocytes, Macrophages, and 
Pancreatic β-Cells
Anik Boudreau 1, Susan J. Burke 1, J. Jason Collier 1, Allison J. Richard 1, David M. Ribnicky3,  
and Jacqueline M. Stephens 1,2
Objective: An ethanolic extract of Artemisia scoparia (SCO) improves 
adipose tissue function and reduces negative metabolic consequences 
of high-fat feeding. A. scoparia has a long history of medicinal use across 
Asia and has anti-inflammatory effects in various cell types and disease 
models. The objective of the current study was to investigate SCO’s ef-
fects on inflammation in cells relevant to metabolic health.
Methods: Inflammatory responses were assayed in cultured adipocytes, 
macrophages, and insulinoma cells by quantitative polymerase chain re-
action, immunoblotting, and NF-κB reporter assays.
Results: In tumor necrosis factor α–treated adipocytes, SCO mitigated 
ERK and NF-κB signaling as well as transcriptional responses but had no 
effect on fatty acid–binding protein 4 secretion. SCO also reduced levels 
of deleted in breast cancer 1 protein in adipocytes and inhibited inflam-
matory gene expression in stimulated macrophages. Finally, in pancreatic 
β-cells, SCO decreased NF-κB–responsive promoter activity induced by 
IL-1β treatment.
Conclusions: SCO’s ability to promote adipocyte development and 
function is thought to mediate its insulin-sensitizing actions in vivo. Our 
findings that SCO inhibits inflammatory responses through at least two 
distinct signaling pathways (ERK and NF-κB) in three cell types known to 
contribute to metabolic disease reveal that SCO may act more broadly 
than previously thought to improve metabolic health.
Obesity (2020) 28, 1726-1735. 
Introduction
The obesity epidemic and its associated metabolic disorders are among the major health chal-
lenges of our time (1). Adipose tissue plays a crucial role in these metabolic disease states, 
and disruptions in adipocyte development and function negatively impact whole-body insu-
lin sensitivity and systemic metabolic health (2). Adipocyte differentiation and adipose tis-
sue expansion are often impaired in obese states, leading to insulin resistance and metabolic 
dysregulation (3,4). In addition, obesity and insulin resistance are associated with enhanced 
basal lipolysis rates, which exacerbate metabolic disease (reviewed in Morigny et al.) (5). 
Inflammatory processes in adipose tissue are also a prominent feature of obesity and the 
metabolic syndrome, and there is extensive cross talk between inflammation, adipogenesis, 
© 2020 The Obesity Society. Received: 7 February 2020; Accepted: 11 May 2020; Published online 2 August 2020. doi:10.1002/oby.22912
1 Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA. Correspondence: Jacqueline Stephens (jsteph1@lsu.edu) 2 Department of Biological 
Sciences,  Louisiana State University, Baton Rouge, Louisiana, USA 3 Department of Plant Biology and Pathology,  Rutgers University, New Brunswick, 
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Study Importance
What is already known?
►	Adipose tissue inflammation plays a crit-
ical role in whole-body metabolic func-
tion in the context of obesity.
►	An ethanolic extract of Artemisia sco-
paria (SCO) improves measures of adi-
pocyte and adipose tissue function as 
well as whole-body insulin sensitivity in 
a mouse model of diet-induced obesity.
What does this study add?
►	SCO inhibits inflammatory gene ex-
pression in cultured adipocytes and 
macrophages.
►	SCO inhibits ERK signaling in adipocytes 
as well as NF-kB signaling in adipocytes 
and pancreatic β-cells.
How might these results change the 
direction of research?
►	SCO’s effects on adipocyte function 
and development have been well stud-
ied. Our current results indicate that 
SCO may be acting on various cell 
types, through several mechanisms, 
to mitigate obesity-related metabolic 
dysfunction; this opens up new direc-
tions for the investigation of SCO’s 
properties.
►	Our new data support the further study 
of SCO as a dietary supplement to pro-
mote metabolic resilience.
Obesity
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endocrine function, and lipid metabolism in adipose tissue (5,6). Because 
of its importance in obesity and diabetes, adipose tissue is considered a 
valuable target for therapeutic intervention (2).
Botanicals have an extensive history of medicinal use across most, if 
not all, cultures the world over, and plants have long been an important 
source of pharmaceutical compounds. Notably, metformin, the first-line 
drug in treating type 2 diabetes mellitus, was derived from galegine, a 
bioactive first isolated from Galega officinalis, also known as goat’s 
rue or French lilac (7). Screening efforts in our laboratory identified 
an extract of Artemisia scoparia (SCO) as a potent enhancer of adi-
pocyte differentiation in vitro. Subsequent studies in a diet-induced 
obesity (DIO) mouse model have shown that SCO also has metaboli-
cally beneficial effects on adipose tissue in vivo (8,9). In addition, SCO 
supplementation improves whole-body insulin sensitivity and reduces 
circulating levels of fatty acids and triglycerides (8-10). More recently, 
we demonstrated that SCO can act on adipocytes in vitro to reduce 
lipolysis induced by the inflammatory cytokine tumor necrosis factor 
alpha (TNFα) (11).
A. scoparia has a well-documented history of medicinal use (12,13), 
and it has been shown to have a wide range of effects in disease mod-
els related to Alzheimer disease, renal oxidative stress, hepatotoxicity, 
hypertension, and others (14-17). More specifically, anti-inflammatory 
effects of A. scoparia have been described in a wide range of cell types 
and contexts (18-20). In adipose tissue, TNFα secreted from resident 
macrophages is a principal mediator of obesity-associated inflammation 
(6,21,22). Given the important role of adipose tissue inflammation in 
obesity-related metabolic dysfunction, we examined the ability of SCO 
to regulate TNFα action and inflammatory gene expression in adipo-
cytes. We observed that SCO reduced effects of TNFα on inflammatory 
cytokine expression and nuclear factor-κB (NF-κB) activation. SCO also 
reduced nuclear levels of deleted in breast cancer 1 (DBC1, also known 
as cell cycle and apoptosis regulator 2 [CCAR2]), a protein associated 
with impaired metabolic function (23-26). Although SCO reduced lip-
olysis induced by TNFα, it had no effect on TNFα-induced secretion 
of fatty acid–binding protein 4 (FABP4), which has been shown to be 
enhanced by lipolytic stimuli and reduced by interventions that inhibit 
lipolysis (27,28). Finally, we observed anti-inflammatory effects of SCO 
in two other cell types critical in metabolic disease states: macrophages 
and pancreatic β-cells. Taken together, data presented herein, as well as 
previously published studies, support further investigation of SCO as a 
potential therapeutic in the treatment of metabolic disease.
Methods
Botanical extract source and preparation
A. scoparia plants were grown and harvested, and ethanolic extracts 
were prepared as previously reported (8,11). SCO extracts were dis-
solved in dimethyl sulfoxide (DMSO) at 1000X final concentration (10 
mg/mL and 50 mg/mL, respectively, for 10- or 50-μg/mL treatments).
Adipocyte cell culture and treatments
3T3-L1 preadipocytes were grown and differentiated as previously de-
scribed (8). Briefly, cells were grown in high-glucose DMEM supple-
mented with 10% bovine calf serum. Cells were induced to differentiate 
2 days after reaching confluence in DMEM plus 10% fetal bovine serum 
(FBS) containing 0.5mM 3-isobutyl-1-methylxanthine (IBMX), 1μM 
dexamethasone, and 1.7μM insulin. Cells were fed 48 to 72 hours later 
with DMEM plus 10% FBS and 0.425μM insulin and then every 48 to 
72 hours with DMEM plus 10% FBS. DMEM, IBMX, dexamethasone, 
and insulin were obtained from Sigma-Aldrich (St. Louis, Missouri); 
calf serum and FBS were purchased from Hyclone (GE Life Sciences, 
Logan, Utah). Treatments with SCO were initiated between 6 and 13 
days after induction of differentiation. Murine TNFα was purchased 
from Life Technologies (Carlsbad, California), dissolved at 0.5μM in 
phosphate-buffered saline (PBS) containing 0.1% bovine serum albu-
min (BSA), and added to cell culture media at the final concentrations 
indicated in figure legends.
Macrophage cell culture and treatments
RAW 264.7 macrophages were cultured in high-glucose DMEM sup-
plemented with 10% FBS. Cells were pretreated for 2 hours with SCO, 
and then lipopolysaccharide (LPS) from Escherichia coli 0111:B4 
strain (InvivoGen, San Diego, California) was added for an additional 
5.5-hour incubation before harvest.
Insulinoma cell culture and treatments
The 832/13 rat insulinoma cells were cultured as previously de-
scribed (29) and transfected with an adenoviral luciferase reporter 
construct under the control of five copies of a consensus NF-κB el-
ement (vector obtained from Vector Biolabs, catalog number 1740; 
Malvern, Pennsylvania). A total of 12 hours after transduction, cells 
were treated overnight with 5 or 10 μg/mL of SCO or Artemisia san-
tolinaefolia and then for 4 hours with 1 ng/mL of interleukin (IL)-1β. 
Luciferase reporter activity was assessed by luminometry and nor-
malized to total protein content.
RNA isolation and gene expression analysis
Treated cells were harvested in cell lysis RLT Buffer (Qiagen, Hilden, 
Germany). Lysates were stored at −80°C prior to RNA extraction using 
the RNeasy Mini Kit (Qiagen). The High-Capacity Reverse Transcription 
Kit (Applied Biosystems, Foster City, California) was used to re-
verse transcribe the RNA samples, and gene expression was assayed 
by quantitative polymerase chain reaction (PCR) with Takara SYBR 
premix (Takara Bio USA, Mountain View, California) on the Applied 
Biosystems 7900HT system (cycling conditions: 2 minutes at 50°C; 10 
minutes at 95°C; 40 cycles of 15 seconds at 95°C and 1 minute at 60°C; 
dissociation stage: 15 seconds at 95°C, 15 seconds at 60°C, and 15 sec-
onds at 95°C with end step ramp rate of 2%). Data were analyzed using 
SDS 2.3 or 2.4 software (Applied Biosystems, Foster City, California). 
Target gene data were normalized to the reference gene non-POU-do-
main–containing, octamer-binding (Nono). Primers were obtained from 
Integrated DNA Technologies (Skokie, Illinois), and sequences were as 
follows: Nono forward: 5’-CATCATCAGCATCACCACCA-3’, reverse: 
5’-TCTTCAGGTCAATAGTCAAGCC-3’; C-C motif chemokine ligand 
2 (Ccl2, also known as monocyte chemoattractant protein 1 [Mcp1]) for-
ward: 5’-GCAGAGAGCCAGACGGGAGGA-3’, reverse: 5’-TGGGG 
CGTTAACTGCATCTGG-3’; l6 forward: 5’-TCCTCTCTGCAAGA 
GACTTCCATCC-3’, reverse: 5’-AAGCCTCCGACTTGTGAAGTG 
GT-3’; lipocalin 2 (Lcn2) forward: 5’-TGCAAGTGGCCACCACG 
GAC-3’, reverse: 5’-GCATTGGTCGGTGGGGACAGAGA-3’; ni-
tric oxide synthase 2 inducible (Nos2 or iNos) forward: 5’-CCCTCC 
TGATCTTGTGTTGGA-3’, reverse: 5’-TCAACCCGAGCTCCTG 
GAA-3’; Tnfa forward: 5’-AGACCCTCACACTCAGATCA-3’, re-
verse: 5’-TCTTTGAGATCCATGCCGTTG-3’.
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Protein samples and immunoblotting
For whole-cell extract preparation, adipocyte monolayers were har-
vested in radioimmunoprecipitation assay buffer (30) containing the fol-
lowing protease and phosphatase inhibitors: 1mM phenylmethylsulfonyl 
fluoride (PMSF), 1μM pepstatin, 50 trypsin inhibitory milliunits of apro-
tinin, 10μM leupeptin, 1mM 10-phenanthroline, 0.2mM sodium ortho-
vanadate, and 100μM sodium fluoride. Lysates were stored at −80°C and 
then thawed, passed through a 20 gauge needle three times, and clarified 
by centrifugation at 13,000g. Supernatants were recovered, and protein 
concentrations were determined by bicinchoninic acid assay (Sigma-
Aldrich). Equal amounts of protein from each sample were loaded onto 
polyacrylamide gels, subjected to electrophoresis, and transferred to 
nitrocellulose. Standard immunoblotting techniques were applied to 
probe for target proteins. Primary antibodies were purchased from Cell 
Signaling Technologies (Danvers, Massachusetts) for extracellular sig-
nal-regulated kinase (ERK) 1/2, CCAR2 (DBC1), β-actin, and NF-κB 
p65; from R&D Systems (Bio-Techne, Minneapolis, Minnesota) for 
LCN2; from Promega (Madison, Wisconsin) for phosphorylated ERK 
1/2 (active mitogen-activated protein kinase, or MAPK); and from 
Abcam (Cambridge, Massachusetts) for FABP4. Detection was per-
formed with horseradish peroxidase–conjugated antibodies from Jackson 
Immunoresearch (West Grove, Pennsylvania). Autoradiography films 
were scanned and densitometry analysis performed using ImageStudio 
software from Li-Cor Biosciences (Lincoln, Nebraska).
Subcellular fractionation
After treatment, adipocytes were harvested in nuclear homogenization 
buffer (NHB) (20mM Tris pH 7.4, 10mM NaCl, and 3mM MgCl2). 
IGEPAL CA-630 (Sigma-Aldrich) was added to the cell suspension at a 
final concentration of 0.15% prior to Dounce homogenization on ice. The 
nuclear fraction was pelleted by centrifugation at 517g, washed in NHB, 
and resuspended in immunoprecipitation buffer. NHB and immunopre-
cipitation buffer were supplemented with protease and phosphatase inhib-
itors. Protein concentrations were determined by bicinchoninic acid assay.
FABP4 secretion and lipolysis assays
Cells pretreated for 3 days with SCO or DMSO vehicle were treated 
overnight with or without 0.75nM TNFα. The following morning, 
culture medium was replaced with lipolysis incubation medium 
(low-glucose DMEM + 2% BSA). Cells treated with TNFα overnight 
were treated with the same concentration of TNFα for the lipolysis/
FABP4 secretion analysis. The remaining cells were treated with ei-
ther vehicle (controls) or 2nM or 10μM isoproterenol. Conditioned 
media samples were collected after 4 hours and analyzed for FAPB4 
content by immunoblotting. Lipolysis was also assessed by measur-
ing glycerol concentrations in the samples, using free glycerol re-
agent from Sigma-Aldrich.
Results
SCO inhibits TNFα-induced inflammatory gene 
expression in 3T3-L1 adipocytes
Our previous studies have demonstrated that SCO could reduce pro-
tein levels of the inflammatory cytokine CCL2 (also known as MCP-1) 
in the adipose tissue of high-fat diet-fed mice and inflammatory gene 
expression in cultured adipocytes (9). Hence, we have sought to char-
acterize the cell-autonomous anti-inflammatory effects of SCO in 3T3-
L1 adipocytes treated with TNFα, a predominant mediator of adipose 
tissue inflammation that increases the expression of several inflamma-
tory genes in adipocytes (21). As shown in Figure 1, pretreatment of 
3T3-L1 adipocytes with 50 μg/mL of SCO significantly diminished 
TNFα-induced expression of Ccl2 and Il6, consistent with previously 
published studies (8), as well as Lcn2 and Nos2 or (iNos). We also ex-
amined the time course for induction of these genes and for the effects 
of SCO. As shown in Figure 2, the temporal patterns of induction by 
TNFα and inhibition by SCO were different for all four genes assayed. 
While Ccl2 and Lcn2 both increased gradually over the 8-hour TNFα 
treatment, the effects of SCO were distinct. In the case of Ccl2, SCO 
significantly inhibited TNFα-induced gene expression at all time points. 
Yet, for Lcn2, SCO increased expression in basal conditions at all time 
points and at the early time points of TNFα treatment (1 and 2 hours). 
After 4 hours of TNFα treatment, SCO-treated cells had equivalent 
Lcn2 expression to the controls, and after 8 hours, expression was sig-
nificantly lower in SCO-treated cells. Induction of Il6 gene expression 
by TNFα was observed at all time points, but the response was biphasic. 
Specifically, expression strongly increased at 1 hour, subsided at 2 and 
4 hours, and then substantially increased again at 8 hours. This same 
pattern of TNFα induction was observed in SCO-treated cells but with 
lower Il6 expression levels than without SCO at all time points. SCO 
attenuation of the TNFα effect on Il6 was significant at 1, 4, and 8 hours 
but not at 2 hours. Finally, Nos2 expression and nitric oxide production 
induced by TNFα have been implicated in the regulation of adipocyte 
lipolysis (31). TNFα induced Nos2 expression starting at the 2-hour 
time point, and SCO significantly but modestly inhibited TNFα’s ef-
fects, consistent with its previously described antilipolytic actions (11).
Figure 1  SCO inhibits TNFα-induced expression of inflammatory genes in 3T3-L1 
adipocytes. Mature 3T3-L1 adipocytes were pretreated with 50 μg/mL of SCO for 3 
days and then with 0.75nM TNFα for 18 hours. Cells were harvested for RNA isolation, 
and gene expression was assayed by quantitative PCR. Target gene data were 
normalized to the reference gene Nonoand expressed as percent of TNFα-induced 
values. Data are shown as means ± SE; n = 4 biological replicates per condition. 
N.D.: Nos2 was below detection level for the quantitative PCR assay. Data for each 
gene were analyzed by one-way ANOVA (for Ccl2, Il6, and Lcn2) or t test (for Nos2). 
Significance was expressed as ***P < 0.001, ****P < 0.0001 vs. TNFα-only controls. 
Results were replicated in two additional experiments on independent batches of 
cells. Ctl, vehicle-only control.
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SCO inhibits TNFα-induced LCN2 secretion in 
3T3-L1 adipocytes
LCN2 is a proinflammatory mediator secreted by adipocytes (re-
viewed in Li et al.) (32). We have previously shown that LCN2 ex-
pression and secretion are induced by TNFα in 3T3-L1 adipocytes 
(33). As shown in Figure 3, the TNFα-induced expression and se-
cretion of LCN2 from adipocytes were substantially reduced in 
the presence of SCO. These observations are consistent with the 
ability of SCO to impair TNFα induction of Lcn2 gene expression 
(Figures 1-2).
SCO reduces total and phosphorylated ERK levels
In adipocytes, TNFα signaling mediates transcriptional regulation 
of numerous target genes involved in adipocyte function (inflamma-
tion, insulin signaling, lipolysis, endocrine function, stress responses) 
through the activation of several signaling pathways (reviewed in 
Cawthorn et al.) (21), including the MAPK ERK. To further charac-
terize the effects of SCO in the context of TNFα action in adipocytes, 
we examined ERK activation in the presence or absence of SCO. As 
shown in Figure 4, TNFα regulates both the expression of ERK and 
its activation, as judged by phosphorylation. TNFα induces ERK phos-
phorylation, and this activation is reduced in the presence of SCO. We 
also observed that total ERK1/2 levels were modulated by both TNFα 
(increased) and SCO (decreased). Comparison of the ratios of phos-
phorylated ERK 1/2 to total ERK 1/2 revealed that the effect of SCO on 
relative ERK activation was not significant.
SCO inhibits TNFα-induced nuclear translocation 
of NF-κB and reduces nuclear levels of DBC1 in 
3T3-L1 adipocytes
Another major signaling pathway engaged by TNFα in adipocytes is 
the inhibitor of nuclear factor-κB kinase (IKK)/NF-κB pathway. TNFα 
causes phosphorylation of the IKK complex as well as phosphoryla-
tion and degradation of its target, inhibitor of NF-κB, resulting in the 
translocation of NF-κB to the nucleus. In order to determine whether 
SCO could modulate the TNFα activation of NF-κB in fat cells, we 
treated 3T3-L1 adipocytes with TNFα, with or without a 3-day SCO 
pretreatment. The cytosolic and nuclear compartments were analyzed 
Figure 2 Time course of TNFα- and SCO-induced changes in inflammatory gene expression. Mature 3T3-L1 adipocytes were pretreated with 50 μg/mL of SCO or DMSO 
vehicle for 3 days prior to harvest. Media was replaced with low-glucose DMEM supplemented with 2% BSA, and cells were treated with 0.75nM TNFα or 0.1% BSA vehicle for 
the times indicated and harvested for RNA isolation. Expression of the inflammatory genes was assessed by quantitative PCR and normalized to the reference gene Nono. One-
way ANOVA was performed for each time point. ##P < 0.01, ###P < 0.001, and ####P < 0.0001, effect of TNFα vs. control; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, 
effect of SCO vs. respective controls (control or TNFα only). Results were replicated on an independent batch of cells.
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by immunoblotting. As shown in Figure 5, TNFα treatment produced 
a very robust increase in nuclear levels of the NF-κB p65 subunit, and 
SCO pretreatment greatly inhibited this response, indicating the ability 
of SCO to interfere with a major inflammatory signaling event.
The nuclear protein DBC1, also known as CCAR2, has been impli-
cated in several processes related to inflammation, adipocyte biology, 
and insulin resistance (23-25). Recent work in our laboratory has 
described a role for DBC1 in regulating TNFα-induced lipolysis in 
3T3-L1 adipocytes (26). We examined DBC1 protein levels in cyto-
solic and nuclear fractions in TNFα-treated cells in the presence and 
absence of SCO (Figure 5) and found that SCO-treated adipocytes had 
less nuclear DBC1 in both basal and TNFα-stimulated conditions. As 
previously reported, DBC1 is not detected in the cytosol of cultured 
adipocytes (26).
SCO does not reduce TNFα- or isoproterenol-
induced FABP4 secretion
In addition to inducing expression of inflammatory mediators in adi-
pocytes, TNFα also stimulates lipolysis, thereby increasing circulat-
ing fatty acid levels and promoting further metabolic dysregulation in 
obesity and insulin-resistant states (5). We have previously shown that 
SCO inhibits TNFα-induced but not adrenergic-stimulated lipolysis in 
adipocytes (11). FABP4 is secreted from adipocytes and adipose tissue 
in response to lipolytic conditions, including exposure to forskolin, cy-
clic adenosine monophosphate (cAMP), or isoproterenol (27,28). To 
our knowledge, the effects of TNFα on FABP4 secretion have not been 
reported. Therefore, we induced lipolysis in adipocytes using TNFα or 
isoproterenol, with or without SCO pretreatment, and measured FABP4 
levels in the conditioned medium to assess whether TNFα could in-
duce secretion of FABP4 in 3T3-L1 adipocytes under prolipolytic con-
ditions. Consistent with previous studies, both doses of isoproterenol 
tested stimulated FABP4 secretion (Figure 6A). We also made the novel 
observation that TNFα promoted secretion of FABP4 in the presence 
and absence of SCO (Figure 6A). Additionally, we examined lipoly-
sis, as measured by glycerol release, in these adipocytes. As shown in 
Figure 6B, SCO did not attenuate isoproterenol-induced lipolysis but 
did attenuate TNFα-induced lipolysis. SCO had no effect on FABP4 se-
cretion in any of the treatments (Figure 6A). Of note, SCO significantly 
reduced lipolysis, but not FABP4 secretion, in TNFα-treated adipocytes.
SCO reduces LPS-induced expression of Il1b and 
Nos2 (iNos) but not Tnfa in macrophages
Adipose tissue macrophages promote inflammation and contribute to 
adipocyte dysfunction in obesity and insulin-resistant states (6,22). 
Hence, we examined the ability of SCO to modulate inflammatory 
gene expression in RAW 264.7 cells treated with LPS. As shown in 
Figure 7, LPS elicited a robust induction of Tnfa, Il1b, and Nos2. SCO 
pretreatment inhibited the LPS effect on Il1b and Nos2 in a dose-depen-
dent manner but had no effect on the induction of Tnfa gene expression 
by LPS, revealing a gene-specific anti-inflammatory effect of SCO in 
these cultured macrophages.
SCO reduces IL-1β–induced NF-κB activation in 
cultured pancreatic beta cells
NF-κB signaling is crucial in mediating the inflammatory transcrip-
tional responses that contribute to pancreatic β-cell dysfunction in 
Figure 3 SCO inhibits TNFα-induced cellular levels and secretion of LCN2 in adipocytes. Mature 3T3-L1 adipocytes 
were pretreated with 50 μg/mL of SCO or DMSO vehicle for 3 days prior to harvest. On the last day of SCO treatment, 
cells were treated with 0.75nM TNFα or 0.1% BSA vehicle for 18 hours. Medium on all cells was then replaced with 
low-glucose phenol-red-free DMEM containing either vehicle or 0.75nM TNFα. After 4 hours, samples of conditioned 
media were collected, and cells were harvested in radioimmunoprecipitation assay buffer for immunoblotting. A total 
of 125 μg (media) or 75 μg (whole-cell extracts) of total protein was loaded in each well.
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diabetes (34-38). To determine whether SCO could regulate NF-κB 
activation in β-cells, we transduced 823/13 rat insulinoma cells with 
a NF-κB luciferase reporter and then treated cells with SCO at 5 or 10 
μg/mL or vehicle overnight before stimulating cells with IL-1β for 4 
hours. IL-1β treatment induced NF-κB promoter activation 28.6-fold 
over untreated controls. As shown in Figure 8, we observed a dose- 
dependent reduction in NF-κB promoter activity in the presence of 
SCO. The higher dose of SCO resulted in a statistically significant 
decrease in IL-1β–induced NF-κB promoter activity. This effect was not 
observed with an extract from A. santolinaefolia, a different Artemisia 
species also known to have adipogenic effects in vitro as well as some 
metabolically favorable effects in a mouse DIO model (9).
Discussion
The impacts of obesity, metabolic syndrome, and T2DM clearly jus-
tify the search for novel therapeutic approaches, and adipose tissue 
is intensely studied as a target for such interventions. Obesity is con-
sidered a proinflammatory state, and the importance of adipose tissue 
inflammation in the progression of insulin resistance is well docu-
mented. In obesity, infiltration and activation of proinflammatory im-
mune cells (particularly macrophages) in adipose tissue contribute to 
impaired adipocyte differentiation and function as well as to systemic 
insulin resistance, mediated in large part by the paracrine actions of 
macrophage-derived TNFα on adipocytes (6,21,22). The present study 
demonstrates that SCO can impede inflammatory processes through at 
least two different signaling pathways (MAPK and NF-κB) and in three 
cell types relevant to metabolic health (adipocytes, macrophages, and 
pancreatic β-cells).
In adipocytes, we discovered gene-specific temporal patterns of induc-
tion by TNFα and inhibition by SCO. For example, three of the four 
genes we examined showed a steady increase over an 8-hour TNFα 
treatment, while the fourth gene, Il6, showed a biphasic response 
(Figure 2). Also, though SCO reduced expression of Il6, Mcp1, and 
iNos in all TNFα-treated conditions, SCO pretreatment increased Lcn2 
expression in basal conditions and at the early time points of TNFα 
treatment but was inhibitory with longer TNFα treatments. Given the 
low levels of Lcn2 expression in basal conditions and at early time 
Figure 4 SCO reduces total and phosphorylated ERK levels in 3T3-L1 adipocytes. Mature 3T3-L1 adipocytes were pretreated with 50 μg/mL of SCO or DMSO vehicle for 3 days, 
with 18-hour (overnight) serum deprivation (0.3% BSA) and 0.5nM TNFα treatment on the last day. Cells were harvested in radioimmunoprecipitation assay buffer and analyzed 
by Western blot. Blot images and quantitation data are shown. Data expressed as foldchange (FC) vs. control (CON). *P < 0.05 and ***P < 0.001, effect of SCO vs. respective 
controls (CON or TNFα only); #P < 0.05, effect of TNFα vs. CON. NS, not significant. Results were replicated in two additional experiments on independent batches of cells.
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points of TNFα induction, SCO’s effects on these inflammatory genes 
under basal conditions are not likely to have physiological relevance. 
Likewise, SCO’s inhibition of Nos2 expression is modest after 2, 4, or 
8 hours of TNFα treatment compared with the robust induction with 
TNFα and may not be of any biological significance. Taken together, 
these observations underscore the complexity of inflammatory signal-
ing and suggest that SCO may be acting through distinct mechanisms 
on different genes.
Activation of the MAPK ERK by phosphorylation mediates some of the 
effects of TNFα in adipocytes (21). Although phosphorylated to total 
ERK1/2 ratios were not significantly altered by SCO pretreatment, 
TNFα-treated cells had lower absolute levels of active phosphorylated 
ERK 1/2 when pretreated with SCO (Figure 4), indicating suppression 
of MAPK signaling. This effect on ERK activation could contribute 
to the SCO-mediated reductions in inflammatory gene expression we 
observed, particularly that of Lcn2, whose expression has been shown 
to be dependent on ERK 1/2 activation (39). The ability of SCO to 
decrease total levels of ERK 1/2 implies that SCO pretreatment may 
alter its transcription, translation, or stability. Avenues for further inves-
tigation of this observation could include studies of protein stability, 
unfolded protein response, and endoplasmic reticulum stress, among 
others. At this time, we do not know whether the effect of SCO on ERK 
expression is required for its anti-inflammatory actions.
The NF-κB pathway is also well characterized and known to mediate 
TNFα’s effects on inflammatory cytokine gene transcription through 
nuclear translocation of the p65 subunit of NF-κB, and NF-κB sig-
naling events are involved in inflammation-related metabolic disease 
(reviewed in Baker et al.) (40). A study in LPS-stimulated macrophages 
has shown that the total flavonoid fraction of A. scoparia could inhibit 
inflammatory signaling through MAPK and NF-κB (19). Our studies 
in adipocytes reveal that SCO caused substantial inhibition of both 
pathways in adipocytes and provide further evidence that SCO impedes 
inflammatory signaling pathways in fat cells.
Figure 5 SCO reduces nuclear DBC1 and TNFα-induced p65 nuclear translocation 
in 3T3-L1 adipocytes. Mature 3T3-L1 adipocytes were pretreated for 3 days with 
50 μg/mL of SCO or DMSO vehicle and then with 0.5nM TNFα for 20 minutes. 
Cells were harvested, and the cytosolic and nuclear compartments were isolated. 
Immunoblotting was performed to detect DBC1 and the p65 subunit of NF-κB. ERK 
1/2 was included as a loading control for the cytoplasmic fractions.
Figure 6 SCO does not reduce TNFα- or isoproterenol-induced FABP4 secretion. Mature 3T3-L1 adipocytes were pretreated with 50 μg/mL of SCO or DMSO vehicle for 3 
days prior to harvest. On the last day of SCO treatment, cells were treated with 0.75nM or 0.1% BSA vehicle overnight (18 hours). The following day, medium on all cells was 
replaced with low-glucose phenol-red-free DMEM containing either vehicle, 0.75nM TNFα, or 2nM or 10μM isoproterenol (ISO). Samples of conditioned media were collected 
after 4 hours. (A) Total protein (75 μg) was loaded in each well and analyzed with standard immunoblotting techniques. Membranes were probed for FABP4; adiponectin 
(ADPN) was used as a loading control. Blot images are shown. (B) Conditioned media (50 μL) was also assayed for glycerol content. Effects of TNFα and ISO vs. control in 
the DMSO condition were analyzed by one-way ANOVA; ##P < 0.01 and ####P < 0.0001 vs. DMSO control. Effect of SCO was assessed in each condition vs. the respective 
DMSO condition by t tests; *P < 0.05. All other interactions were nonsignificant. WCE, whole-cell extract control lysate.
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DBC1 is a multi-functional protein proposed to be at the interface 
between aging, cancer, and metabolism (41). Loss of DBC1 in adipo-
cytes inhibits TNFα–induced lipolysis (26), and DBC1 knockout mice 
are protected from several metabolic effects of DIO (23). In addition, 
DBC1 knockdown in adipocytes promotes adipogenesis and reduces 
inflammatory cytokine expression (24,25), whereas in B cells, DBC1 
has been shown to interact with proteins of the IKK complex, which 
directly regulates NF-kB signaling (42). Taken together, these studies 
link DBC1 inhibition with favorable metabolic effects. We have shown 
that SCO reduces DBC1 protein levels in adipocytes (Figure 5), which 
could contribute to its anti-inflammatory, antilipolytic, and antidiabetic 
properties. However, future studies will be needed to determine if loss 
of DBC1 plays an important role in the ability of SCO to promote met-
abolic health.
Elevated plasma levels of FABP4 are associated with obesity and 
insulin resistance in both mice and humans, and inhibition of plasma 
FABP4 activity improves glucose homeostasis in DIO mice (43). Acute 
activation of cAMP- or cyclic guanosine monphosphate (cGMP)- 
dependent protein kinases (PKA and PKG, respectively) by increased 
intracellular cAMP or cGMP levels, respectively, stimulates lipoly-
sis and has been shown to promote FABP4 secretion from adipocytes 
(28,44). The mechanisms involved in the lipolytic effects of TNFα have 
not been fully elucidated, but they are distinct from those induced by 
fasting or adrenergic stimulation (5,21). We report here that induction 
of lipolysis by TNFα is associated with increased FABP4 secretion 
(Figure 6A). Though suppression of lipolysis with insulin or through 
pharmacological inhibition of PKA, PKG, or hormone-sensitive lipase 
has been shown to reduce FABP4 secretion in PKA- or PKG-stimulated 
conditions (27), we observed that SCO had no effect of TNFα-induced 
FABP4 secretion (Figure 6B) despite its ability to inhibit lipolysis, 
indicating that FABP4 secretion is not necessarily coupled to lipolysis. 
These data also argue against the involvement of FABP4 secretion in 
SCO’s insulin-sensitizing effects.
Figure 8 SCO inhibits IL-1β–stimulated NF-κB promoter activity in rat insulinoma cells. 832/13 cells were transduced 
with an adenovirus overexpressing a luciferase reporter construct driven by a promoter containing five copies of 
a consensus κB element (5xNF-κB-Luc). A total of 12 hours after transduction, cells were untreated or treated 
overnight with 5 and 10 μg/mL of SCO or an extract of Artemisia santolinaefolia (SAN). Cells were then stimulated 
for 4 hours with 1 ng/mL of IL-1β. NF-kB promoter activity was induced 28.6-fold (for the SCO experiment) or 
31.1-fold (for the SAN experiment) by IL-1b treatment (not shown). Promoter activity in cells pretreated with the 
extracts is expressed as percent of this maximal induction. Data are means ± SEM of four individual experiments, 
each performed in triplicate. **P < 0.01 vs. control.
Figure 7 SCO reduces LPS-induced expression of Il1b and Nos2 (iNos) but not Tnfa in 
RAW 264.7 macrophages. RAW macrophages were pretreated with 10 or 50 μg/mL 
of SCO for 2 hours and then with 1 μg/mL of LPS for 5.5 hours. RNA was isolated 
and reverse transcribed. Gene expression was assayed by quantitative PCR, using 
Nono as the reference gene, and foldchange was calculated vs. the average of the 
LPS-only condition for each gene. Data are shown as means ± SE; n = 4 biological 
replicates per condition. Data for each gene were analyzed by one-way ANOVA. 
Significance expressed as *P < 0.05 and ****P < 0.0001 vs. LPS-only controls. Results 
were replicated in three independent experiments.
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In LPS-treated RAW 264.7 macrophages, SCO significantly inhib-
ited Il6 and Nos2 expression but had no effect on Tnfa expression 
(Figure 7). This gene-specific response is not entirely unexpected. Toll-
like receptor 4 (TLR4) signaling, which mediates the effects of LPS 
in macrophages, engages two main pathways that utilize distinct sub-
sets of adaptor proteins. The so-called myeloid differentiation primary 
response 88 (MyD88)–dependent arm results in early phase NF-κB 
activation and induction of inflammatory genes, including interleukins. 
The MyD88–independent arm involves activation of toll/interleukin-1 
receptor (TIR) domain-containing adaptor protein inducing interferon 
beta and interferon regulatory factor 3 (TRIF) and induction of genes 
such as the type 1 interferons. Although TNFα is an NF-κB target 
gene, its regulation by TLR4 signaling is complex (45-47). It has been 
shown that activation of the NF-κB–independent TRIF pathway can 
induce early TNFα production and secretion, which in turn leads to a 
later-phase secondary autocrine activation of NF-κB signaling through 
TNFα receptor 1 (48). In addition, transcriptional activation of NF-κB 
target genes is subject to complex regulation by many factors, including 
chromatin structure and epigenetic status of the target genes, as well 
as by various posttranslational modifications of NF-κB subunits and 
variable subunit combinations of its dimers (46,47,49).
Interestingly, in a similar study in macrophages using a preparation of 
total flavonoids from A. scoparia, LPS-induced levels of Il6 and Tnfa 
were both inhibited (19). Although the reason for this discrepancy can-
not be ascertained, LPS treatment in this study was much longer than 
ours (20 vs. 5 hours). Under these more chronic conditions, regulation of 
Tnfa expression is more likely to be NF-κB dependent and thus suscep-
tible to inhibition by SCO. Alternatively, differences in the composition 
of both extracts could explain these results. Analysis of our SCO extract 
by chromatography and mass spectrometry has revealed a complex 
mixture of compounds, many of which are not flavonoids (50). In addi-
tion, plants grown in different locations and conditions yield extracts 
with distinct chemical constituents and bioactivities. Though SCO 
did not inhibit Tnfa gene expression in macrophages (Figure 7), it did 
attenuate the response to TNFα treatment in adipocytes (Figures 1-2), 
which could contribute to improving adipose tissue metabolic function 
in the presence of inflammatory stimuli. Clearly, further studies will 
be needed to fully elucidate the gene-specific effects of SCO in this 
context.
Finally, we have shown that SCO reduces NF-κB–responsive promoter 
activity in pancreatic β-cells. Recruitment of immune cells and activa-
tion of inflammatory pathways are major contributors to the pancreatic 
β-cell dysfunction that occurs with obesity and insulin resistance, and 
NF-κB is known to mediate these processes (36). The finding that SCO 
attenuates a measure of NF-κB activation in cultured β-cells (Figure 8) 
indicates that it can exert anti-inflammatory and metabolically favor-
able effects beyond adipose tissue.
Our laboratory has studied the effects of SCO on adipocyte differenti-
ation and function, as well as in a DIO mouse model, for several years. 
We have now shown that SCO significantly impairs inflammatory sig-
naling and transcriptional responses in three cell types that play critical 
roles in obesity, diabetes, and metabolic syndrome. In addition, we have 
described effects of SCO on adipocyte levels of DBC1, a protein that 
has garnered attention in recent years for its involvement in adipogene-
sis, inflammation, and metabolic dysfunction. We have also discovered 
that FABP4 secretion, known to be induced by various lipolytic agents, 
is stimulated by TNFα, although SCO did not modulate this response. 
Taken together, our findings reveal that SCO interferes with inflam-
matory signaling to attenuate responses that promote metabolic dys-
function and we demonstrate, for the first time, that SCO has favorable 
effects in pancreatic β-cells. These results support further investigation 
of SCO as a potential nutritional supplement to promote metabolic 
health in the context of obesity and insulin resistance.O
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